e-learning
resources
Madrid 2019
Tuesday, 01.10.2019
Pulmonary hypertension: new therapeutic pathways and modalities
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Late Breaking Abstract - Morphine for dyspnea in advanced pulmonary arterial hypertension
D. Christiansen (Winnipeg, Canada), K. Wentlandt (Toronto, Canada), J. Lew (Toronto, Canada), J. Granton (Toronto, Canada)
Source:
International Congress 2019 – Pulmonary hypertension: new therapeutic pathways and modalities
Session:
Pulmonary hypertension: new therapeutic pathways and modalities
Session type:
Thematic Poster
Number:
3948
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
D. Christiansen (Winnipeg, Canada), K. Wentlandt (Toronto, Canada), J. Lew (Toronto, Canada), J. Granton (Toronto, Canada). Late Breaking Abstract - Morphine for dyspnea in advanced pulmonary arterial hypertension. 3948
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: Diagnostic tools for Obstructive Sleep Apnoea in adults and children
Expert interview: Physiological classification of lung function impairment
Occupational exposures to respiratory diseases: A case-based discussion
Related content which might interest you:
Late Breaking Abstract - Implication of the KATP Sur2b/Kir6.1 in the physiopathology of pulmonary arterial hypertension
Source: Virtual Congress 2021 – Pathogenesis and pathophysiology of pulmonary hypertension
Year: 2021
Late Breaking Abstract - Contribution of STIM-activated TRPC-ORAI channels to the intermittent hypoxia-induced pulmonary hypertension
Source: Virtual Congress 2020 – Cellular stress in respiratory diseases
Year: 2020
Beta-blocker therapy nor hyperoxic breathing lowers ventilatory drive in pulmonary arterial hypertension patients
Source: International Congress 2014 – Pulmonary hypertension: right ventricular function, exercise and gas exchange
Year: 2014
Effect of pulmonary-specific vasodilator therapy in patients with chronic obstructive pulmonary disease and pulmonary hypertension. A retrospective analysis
Source: International Congress 2014 – Pulmonary hypertension in lung disease
Year: 2014
Riociguat improves excessive exercise ventilation in patients with inoperable chronic thromboembolic pulmonary hypertension
Source: Annual Congress 2013 –Pulmonary circulation: chronic thromboembolic pulmonary hypertension, imaging and biomarkers
Year: 2013
Specific pulmonary arterial hypertension therapy in COPD patients with severe pulmonary hypertension
Source: International Congress 2014 – Pulmonary hypertension in lung disease
Year: 2014
HbA1c-levels in patients with operable chronic thromboembolic pulmonary hypertension
Source: International Congress 2014 – Chronic thromboembolic pulmonary hypertension
Year: 2014
Acute haemodynamic effects of adaptive servoventilation therapy in patients with pulmonary arterial hypertension and patients with chronic thromboembolic pulmonary hypertension
Source: International Congress 2015 – Pulmonary hypertension: management
Year: 2015
Limited and heterogeneous arterial narrowing in idiopathic pulmonary hypertension: Rethinking resistance
Source: International Congress 2015 – Pulmonary hypertension: the right ventricle and its load
Year: 2015
Late Breaking Abstract - Feasibility of instrumented ventilatory and functional evaluation in patients with chronic obstructive pulmonary disease
Source: Virtual Congress 2021 – Pulmonary rehabilitation in asthma and COPD
Year: 2021
LATE-BREAKING ABSTRACT: Peak oxygen consumption improves in inoperable, but not operable, chronic thromboembolic pulmonary hypertension after treatment with pulmonary arterial hypertension drugs
Source: Annual Congress 2013 –New physiologic boundaries
Year: 2013
Effects of riociguat in patients with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) following pulmonary endarterectomy (PEA)
Source: International Congress 2014 – Pulmonary hypertension: improving treatment in PAH
Year: 2014
Prognostic role of excessive exercise ventilation in non-operable patients with chronic thromboembolic pulmonary hypertension
Source: International Congress 2016 – Mechanisms of symptoms and exercise limitation in health and disease
Year: 2016
Exercise-induced pulmonary hypertension in patients with systemic sclerosis: Pilot-study
Source: International Congress 2014 – Pulmonary hypertension: clinical management
Year: 2014
Pulmonary hypertension correction in patients with chronic obstructive pulmonary disease and essential hypertension
Source: International Congress 2014 – Pulmonary hypertension in lung disease
Year: 2014
Unique characteristics of patients with pulmonary arterial hypertension associated with congenital heart disease compared to the rest of pulmonary arterial hypertension subgroups
Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology
Year: 2014
Sildenafil improves heart rate variability, pulmonary hemodynamics and functional status in pulmonary arterial hypertension
Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology
Year: 2014
Incidence and outcomes of haemoptysis in patients with operable and non-operable chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH)
Source: International Congress 2016 – Pulmonary hypertension and chronic thromboembolic pulmonary hypertension
Year: 2016
Exertional dyspnoea in pulmonary arterial hypertension
Source: Eur Respir Rev, 26 (145) 170039; 10.1183/16000617.0039-2017
Year: 2017
The incidence of chronic thromboembolic pulmonary hypertension in asympthomatic pulmonary embolism patients
Source: International Congress 2014 – Chronic thromboembolic pulmonary hypertension
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept